RSS

NANOBIOTIX

Nanobiotix, a late clinical-stage nanomedicine company, has launched a research collaboration with Weill Cornell Medicine to begin nonclinical studies evaluating the impact of NBTXR3 on cGAS-STING pathway in mammary cancers. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Late clinical-stage nanomedicine company, Nanobiotix, has announced its cooperation with the University of Texas MD Anderson Cancer Center to run immunotherapeutic pre-clinical research combining NBTXR3 — the company’s lead product — with Nivolumab. more

News

Nanobiotix, a late clinical-stage nanomedicine company, has started a pre-clinical collaboration with the Providence Cancer Institute to study NBTXR3 — a nanoparticle designed for direct injection into cancerous tumours and activation by radiotherapy more

News

A quick review of some recent treatment approvals, clinical studies and general news in curing diseases, affecting patients from top to bottom. more

News

Nanobiotix is expanding and accelerating its clinical development activities, including its head and neck cancer programme and immune-oncology programme. more

News

Nanobiotix, a late-stage clinical nanomedicine company, has announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results of NBTXR3 in soft tissue sarcoma. more

News

The US Food and Drug Administration (FDA) has approved Nanobiotix’s Investigational New Drug (IND) application for the clinical study of NBTXR3 to treat prostate cancer more

News

Late clinical-stage nanomedicine company Nanobiotix has been authorised to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more

News